Previous 10 | Next 10 |
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
2024-03-13 12:32:48 ET More on Autolus Therapeutics BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapie...
LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP inspection by the MHRA in February 2024, Autolus’ N...
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘ Dual T-cell constant β ...
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights ...
2024-02-22 19:04:44 ET Summary BioNTech and Autolus have announced a strategic alliance to advance their autologous CAR-T programs toward market authorization. BioNTech, known for its COVID-19 vaccine, is diverting its focus back to oncology and has a diverse, but immature pipelin...
2024-02-16 07:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-08 11:29:12 ET More on Autolus Therapeutics Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapies, Related Impact On AUTL Autolus Therapeutics: Pivotal Trial Using Familiar Approach, P...
2024-02-08 11:19:57 ET More on Autolus Therapeutics Autolus Upgrades Leadership And Faces CAR-T Approval SA Analysts Comment On FDA Seeking Boxed Warning For CAR-T Cancer Therapies, Related Impact On AUTL Autolus Therapeutics: Pivotal Trial Using Familiar Approach, P...
LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten offering in the United States of 58,333,336 American Depositary Shar...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-g...
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Pha...
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights befo...